Benjamin J. Lieblong
Clinical Trial Coordinator
University of Arkansas for Medical Sciences
staff
Research Areas
Links
Is this your profile? Verify and claim your profile
Biography and Research Information
OverviewAI-generated summary
Benjamin J. Lieblong's research focuses on therapeutic interventions for cervical intraepithelial neoplasia (CIN) and the immune response to vaccination and irradiation. He has investigated the expansion of human papillomavirus (HPV)-specific T cells in recipients of therapeutic vaccines, observing regression of high-grade squamous intraepithelial lesions. His work includes clinical trials evaluating peptide-based HPV therapeutic vaccines, such as PepCan, and their efficacy when combined with adjuvants like Candida, in treating CIN2/3.
Further research by Lieblong examines the influence of the kallikrein-kinin system on cardiac inflammation following local irradiation. He has a publication record of 25 articles, with a total of 401 citations and an h-index of 10. His collaborative network includes researchers from the University of Arkansas for Medical Sciences, such as Martin Hauer-Jensen and Vijayalakshmi Sridharan, with whom he has co-authored multiple publications.
Metrics
- h-index: 10
- Publications: 25
- Citations: 401
Selected Publications
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i> (2025) DOI
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3). (2023) DOI
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed (2021) DOI
Collaborators
Researchers in the database who share publications
Similar Researchers
Based on overlapping research topics